Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAS-119 (TAS-2104) 是一种可口服且具有选择性和有效性的 Aurora A 抑制剂,IC50为1.0 nM。TAS-119 对 Aurora B 也具有抑制作用,IC50 为 95 nM。TAS-119 对 Aurora A 的亲和力比 Aurora B高。TAS-119 具有有效的抗肿瘤活性和潜在的抗有丝分裂活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 797 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 3,190 | 现货 | ||
25 mg | ¥ 6,320 | 现货 | ||
50 mg | ¥ 8,520 | 现货 | ||
100 mg | ¥ 11,500 | 现货 | ||
500 mg | ¥ 22,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,220 | 现货 |
产品描述 | TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95 nM.TAS-119 has a higher affinity for Aurora A than for Aurora B.TAS-119 exhibits potent antitumor activity and potential antimitotic activity. TAS-119 has potent anti-tumor activity and potential anti-mitotic activity. |
靶点活性 | Aurora A:1 nM (IC50), Aurora B:95 nM (IC50) |
体外活性 |
TAS-119 (30-300 nM) dose-dependently enhances cell growth inhibition by three taxanes (Paclitaxel, Docetaxel, and Cabazitaxel) in HeLa cells. TAS-119 induces mitotic accumulation predominantly in tumor cells, compared with that in normal diploid fibroblasts.[1] TAS-119 enhances the antiproliferative effect of Paclitaxel in a variety of human cancer cell lines, including Paclitaxel-resistant cells.[1] |
体内活性 | TAS-119 (5, 10, and 30 mg/kg; oral; twice daily on day 1 and every day on day 2; Nude rats injected with HeLa-luc cells) induced pHH3 at all doses in nude rats with the HeLa-luc xenografts. The treatment induces phosphorylated histone H3 (pHH3) in nude rats with the HeLa-luc xenografts.[1] |
别名 | TAS119, TAS2104, TAS 2104, TAS-2104, TAS 119 |
分子量 | 506.36 |
分子式 | C23H22Cl2FN5O3 |
CAS No. | 1453099-83-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25.32 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9749 mL | 9.8744 mL | 19.7488 mL | 49.372 mL |
5 mM | 0.395 mL | 1.9749 mL | 3.9498 mL | 9.8744 mL | |
10 mM | 0.1975 mL | 0.9874 mL | 1.9749 mL | 4.9372 mL | |
20 mM | 0.0987 mL | 0.4937 mL | 0.9874 mL | 2.4686 mL | |
50 mM | 0.0395 mL | 0.1975 mL | 0.395 mL | 0.9874 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TAS-119 1453099-83-6 Cell Cycle/Checkpoint Chromatin/Epigenetic Aurora Kinase TAS119 TAS2104 TAS 2104 TAS-2104 TAS 119 Inhibitor inhibitor inhibit